the availability of this treatment option. There are 257 transplant hospitals in the United States, 97 of which perform heart transplantations in Centers for Medicare & Medicaid (CMS)-approved centers. 1 On March 1, 2008, the United States had 2684 patients waiting for a heart transplant. 2 In 2007, 2030 heart transplantations were performed in the United States (Table 1 ). Statistics show that men have a slightly higher survival rate than women at 1, 3, and 5 years. According to the Organ Procurement and Transplantation Network (OPTN) database on March 1, 2008, men had an 87.5% 1-year survival in comparison with women at 85.5%. The 3-year survival was 78.8% versus 76.0% and the 5-year survival was 72.3% versus 67.5%, respectively. 2 Given these statistics, careful patient selection, waitlist management, and organ allocation are keys to success. The purpose of this article is to:
1. educate nurses in identification of patients with terminal heart failure who will benefit from cardiac transplantation; and 2. provide quick reference guides regarding patient evaluation and care during the pretransplant phase.
HEART FAILURE
Heart disease continues to be the leading cause of death in the United States, and heart failure is the most common discharge diagnosis for heart disease-related hospital admission. 3 In 2005, it was estimated that 5 300 000 Americans aged 20 and older have heart failure. 4 Approximately 550 000 new cases are diagnosed each year. The incidence of heart failure increases with age and the prevalence approximately doubles with each decade of life. More than 287 000 people in the United States die each year because of heart failure. 5 Heart failure is a syndrome that includes circulatory congestion or inadequate tissue perfusion related to abnormal heart function and associated with neurohormonal abnormalities. 6 Heart failure ultimately results from the heart's inability to pump and can be diagnosed in many ways. Forward versus backward heart failure focuses on abnormal clinical findings of either inadequate tissue perfusion or circulatory congestion. Left-versus right-sided heart failure is similar to the forward versus backward classification. Leftsided heart failure (backward) is more common and presents with elevated left atrial pressures leading to pulmonary congestion, dyspnea, and eventually right-sided heart failure if inadequately treated.
Right-sided heart failure (forward) presents with elevated right atrial pressures and clinical findings of weight gain, elevated jugular venous pressure, hepatic congestion, renal insufficiency, and peripheral edema. Systolic and diastolic dysfunctions are measures of the heart's functioning as a mechanical pump. The difference is easily identified by echocardiogram. The ejection fraction that is reduced or severely reduced is a good indication of systolic dysfunction, whereas patients with diastolic dysfunction have a normal or a hyperdynamic ejection fraction. 6 With systolic dysfunction, the pumping ability of the ventricle is impaired. This causes a decrease in forward blood flow, reduces cardiac output, and results in inadequate tissue perfusion. In diastolic dysfunction, the ventricular filling is defective and the heart is unable to relax and fill, which can be a result of myocardial stiffness or damage. 7 Ultimately, chronic heart failure consists of 2 common components: myocardial failure and congestive failure. The diagnoses used when listing patients for cardiac transplant are categorized into ischemic, nonischemic cardiomyopathy, or other, and are listed for a quick reference in Table 2 .
Assessing optimal heart failure management is a key component in the evaluation for heart transplantation. Cardiac transplantation is considered a final option for the treatment of heart failure and should be restricted to patients who have failed optimal medical and electrical therapies. Heart failure therapy has accomplished major breakthroughs including the introduction of inhibitors of the reninangiotensin-aldosterone system, β-adrenergic blocking agents, newer diuretics, nontransplant surgical therapies, ultrafiltration, implantable cardiac resynchronization, and defibrillating devices. 8 In addition to medical therapeutic interventions, it is necessary to consider high-risk surgical options such as revascularization or valvular repairs. Ventricular assist devices can be used as destination therapy for patients in whom transplantation is not an option.
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PATIENT IDENTIFICATION
Potential candidates for cardiac transplant include patients with (1) terminal heart failure who are unresponsive to optimal medical therapy. These patients are frequently readmitted for decompensated heart failure and are at high risk for death; (2) recurrent unstable angina not amenable to revascularization; and (3) life-threatening dysrhythmias. Patients who are frequently admitted for heart failure are initially treated with intravenous diuretics or ultrafiltration to correct volume overload. Later, these patients decompensate and may be readmitted because of cardiogenic shock requiring inotropic (dopamine, dobutamine, or milrinone infusions) or mechanical hemodynamic support with an intra-aortic balloon pump. They are treated during the immediate crisis, their medications are reviewed to ensure that optimal medication therapy has been provided, and once stabilized, they are discharged home. Patients who continue to require hospital admissions for heart failure should be considered for transplant evaluation.
Potential candidates for cardiac transplant have failed optimal medical therapy, are essentially healthy except their heart disease, emotionally stable, and compliant with medical care, and have the support of family and friends. 9 Table 3 provides a quick reference guide to patient identification and indications for transplant.
ABSOLUTE CONTRAINDICATIONS
Absolute contraindications to cardiac transplantation are listed in Table 4 . Advancing age is determined by an individual center and is based on the overall health of an individual being evaluated for cardiac transplantation. Fixed pulmonary hypertension, defined as a pulmonary vascular resistance (PVR) of more than 5 Wood units (1 Wood unit = 80 dynes) that does not respond to medical intervention, can result in failure of the right ventricle after transplantation. The newly implanted donor heart does not pump against such resistance, which may result in rightsided heart failure and immediate death of the recipient. A recent pulmonary infarct or emboli (within 6 months of the transplant) has been shown to result in a pulmonary abscess in the presence of immunosuppressive therapy required after transplantation. 10, 11 Severe obstructive pulmonary disease, defined as having forced expiratory volume in 1 second (FEV 1 ) of less than 50% predicted, has been associated with difficulties in extubating patients following surgery. These patients have also been subject to frequent pulmonary infections because of the immune suppression medications required after cardiac transplantation. Active peptic ulcer is a contraindication to transplantation because steroid use required before transplantation can contribute to problems with healing after transplantation. The high doses of steroids often required in the first year after transplantation can lead to diverticular rupture in patients with a pre-transplant diagnosis of diverticulitis. Each patient with a history of diverticulitis should be worked up thoroughly to determine the extent of the disease. Symptomatic peripheral vascular disease with evidence of lesions to the cerebral, carotid, or peripheral vasculature may be a precursor for stroke or thromboembolic events that can lead to amputations of affected limbs.
Active infection in transplant candidates can lead to sepsis and become life threatening in the presence of high doses of immune suppression medications required in the immediate postoperative period. Patients with severe or irreversible liver dysfunction defined as cirrhosis on liver biopsy or serum bilirubin of more than 2.5 mg/dL or transaminases of more than 2× normal are at high risk for coagulopathies and liver failure after transplant because of the surgery and the hepatotoxicity of many posttransplant medications. Intrinsic coagulopathies or unexplained anemia should be evaluated by hematology before listing.
An active or a recent malignancy within 5 years should be cleared by oncology because the medications required to decrease the risk of rejection suppress the immune system. This suppression of immune function 220 CRITICAL CARE NURSING QUARTERLY/JULY-SEPTEMBER 2008 would put an active malignancy at greater risk for spreading. Underlying pre-existing diseases such as amyloidosis have demonstrated a brief benefit; however, the rate of recurrence of this disease and its spread to other organs have made this a contraindication to transplantation. 12 Active substance abuse is an absolute contraindication to transplantation. Most centers require patients to be abstinent of drugs and alcohol for at least 6 months before being placed on the waiting list for a new organ. Substance abuse includes illicit drugs or excessive alcohol consumption, defined as men having more than 4 drinks per occasion and women having more than 3 drinks per occasion. Severe mental illnesses or instability and history of medical noncompliance all pose a risk for rejection if medication compliance is not followed. 9, [13] [14] [15] 
RELATIVE CONTRAINDICATIONS
Relative contraindications to cardiac transplant include severe pulmonary hypertension, obesity, cachexia, diabetes, renal dysfunction, and peripheral vascular disease ( Table 5 ). Reversible pulmonary hypertension is defined as a pulmonary artery systolic pressure of 50 mm Hg or more and either a transpulmonary gradient of 15 or more or the pulmonary vascular resistance of 5 Wood units or more that responds to medical intervention. A vasodilator challenge with nitroprusside, nitroglycerine, prostacyclin, or nitric oxide is administered to patients with elevated PVR to determine the reversibility of the pulmonary hypertension. Reversibility is achieved if the PVR is less than 3 Wood units. Obesity is defined as a body mass index (BMI) of more than 30 kg/m 2 or percentage ideal body weight greater than 140% and is associated with heightened risk for infection after transplantation and higher mortality. Therefore, potential candidates are encouraged to lose and maintain these goal weights before listing for transplantation. Cachexia, defined as a BMI of less than 20 kg/m 2 or less than 80% of ideal body weight, leads to risk of poor surgical recovery and healing after transplantation.
Patients with diabetes are evaluated for evidence of end-organ damage and poor glycemic control as evidenced by a glycosylated hemoglobin (HbA 1c ) of more than 7.5. Renal dysfunction is assessed using creatinine clearance under optimal medical therapy, renal ultrasound, and presence of proteinuria. End-stage renal disease is also considered a contraindication. It is defined as a creatinine clearance of less than 50 mL/min or a serum creatinine of more than 2 mg/dL and is associated with an increased risk for dialysis because of intrinsic disease. Pre-existing renal disease is confounded by the toxicities of the immune suppression medications (primarily calcineurin inhibitors) and may contribute to a need for dialysis after transplantation. The extent of peripheral vascular disease (PVD) determines the associated contraindication rating. In the United States, 80% of centers consider asymptomatic PVD a relative contraindication. Active tobacco use is a relative contraindication, and PVD patients are encouraged to complete a smoking cessation program and demonstrate a 6-month period of smoking abstinence as evidenced by random urine nicotine/cotinine levels of less than 50 ng/mL. Human immunodeficiency virus infection is a relative contraindication. For the candidate's overall health, anticipated long-term survival, and infectious disease, physician recommendations are assessed in determining whether transplantation is an option for the candidate. Patients with a stable CD4 + count are candidates of organ transplants. 16 
INITIAL SCREENING
Potential candidates are referred to a cardiologist, a surgeon, or a member of cardiac transplantation team. Indications and contraindications are reviewed to determine candidacy. Medical history and progression of cardiac disease are reviewed. Several questions need to be answered before the initiation of the transplant evaluation. First, has the patient's overall condition been investigated fully enough to be confident that maximal medical and surgical therapies have been provided? After a successful transplant, is the patient expected to resume a normal, active, and functional lifestyle? Does the patient has financial resources to pay for the transplant, posttransplant care, and medications ordered? Is the patient capable of adhering to a strict medical regimen involving multiple medications with potentially unpleasant adverse effects and will the patient return for regular follow-up appointments and biopsies (even if he or she is feeling well)? Finally, does the patient has adequate social support?
CARDIAC TRANSPLANT EVALUATION
The evaluation begins with a complete history and physical examination to determine the etiology of the cardiac disease and if any pre-existing conditions or contraindications exist that would negatively impact a successful transplant outcome. If any potential contraindications are identified, they are evaluated first to determine whether the full evaluation should be pursued. Transplant coordinators provide the patient and the family with education regarding cardiac transplantation to ensure they understand the scope of the evaluation, the waiting period, and the longterm follow-up posttransplantation. This is an important role for transplant coordinators because patients and families often come with preconceived ideas about transplantation. Written educational material is provided to patients and families to reinforce the education provided by transplant coordinators. The transplant evaluation can take place within the outpatient or the inpatient setting and can often be completed within 2 days. This comprehensive, multidisciplinary evaluation is itemized in Table 6 .
SELECTION PROCESS
Following the completion of the cardiac transplant evaluation, the results are compiled and presented to the selection committee. The purpose of this committee is to determine appropriate selection of potential recipients in critical need and who are likely to benefit from this scarce and lifesaving resource. The lack of sufficient organ availability contrasted to the increasing patients in need makes this selection crucial in resource utilization.
The committee may be composed of cardiac surgeons, cardiologists, specialty physicians on the team (infectious disease, endocrinology, psychiatry, etc), nursing, social worker, pharmacist, financial coordinator, and laboratory/immunology specialist. The specific components of the committee meeting are listed in Table 7 . Each member is offered the opportunity to provide input into the treatment recommendation for the potential candidate. This selection committee reviews the full evaluation and then determines the severity of illness and whether the patient has medical or surgical options outside transplant that could be first offered to the patient. Transplant is offered if the committee approves this as the best option for the patient.
Following the meeting, the patient and the referring physician are notified by phone and writing the outcome of the meeting. Patients offered listing for heart transplant are contacted and listed for transplant on the basis of specific center protocols and United Network of Organ Sharing (UNOS) guidelines. 2 
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LISTING
In 1999, the UNOS developed a cardiac organ sharing allocation system that gave priority to the most critically ill patients. Recipients of cardiac transplant are divided into 4 listing categories and the full UNOS description of these listing categories is outlined in Table 8 . Actively listed patients are prioritized on the basis of severity of illness.
Patients given the 1A status are at the highest risk for dying while awaiting trans-plant. Status 1A is given to patients on mechanical device therapy (ventricular assist devices, total artificial heart, intra-aortic balloon pumps, or mechanical ventilators) or receiving continuous pulmonary artery catheter monitoring with the infusions of one highdose inotropic agent or a combination of inotropic agents listed in Table 8 . These patient are recertified every 14 to 30 days on the basis of UNOS criteria, which is stated in Table 8 . If the patient meets criteria for an extension, the attending physician can recertify Table 7 . Cardiac transplant selection Selection team members: Cardiac surgeon, cardiologist, medical physicians on the team (infectious disease, endocrinology, psychiatry, etc), nursing, social worker, pharmacist, financial coordinator, immunologist, chaplain Present patient to the selection committee to determine whether listing is appropriate Entire evaluation is reviewed by the group Psychosocial evaluation is discussed Insurance benefits are discussed; work on prior authorization process Decision regarding listing the patient is determined and noted in the minutes Following the meeting, the patient and the referring physician are notified by phone and writing the outcomes of the meeting the patient and the transplant coordinator updates the UNOS registry. Maintaining accurate listing status is required by the UNOS. Each transplant program is responsible for ensur- to maintain hemodynamic stability and the infusion is reduced, this patient no longer qualifies for status 1A and must be downgraded to status 1B in the UNOS registry. Another example that occurs within the intensive care unit pertains to pulmonary artery monitoring. Some patients have established hemodynamic stability on milrinone 0.5 μg/kg/min (the qualifying inotropic dose justifying status 1A) and the infection risk from longterm use of the pulmonary artery catheter is of concern to the medical team. When the pulmonary artery catheter is removed, the patient must be downgraded to status 1B unless a new catheter is reinserted. Communication between the critical care nurses and transplant coordinators is crucial in maintaining a correct listing status and results in the proper allocation of the organ. Following 30 days as a status 1A listing, patients who have an implanted left and/or right ventricular assist device must have a status 1B listing. This same status applies to patients on a continuous intravenous inotropic infusion of milrinone, dopamine, or dobutamine at any dose. Status 1B candidates do not require hemodynamic monitoring or hospitalization.
Status 2 is assigned to all remaining activated patients who do not meet criteria for status 1A or 1B. Typically, patients in status 2 are home on oral medical therapy.
Status 7 is considered temporarily unsuitable for transplant. The reasons for inactivation can range from being too sick or too well for transplant, outside the transplant center area and not available for transplant, in the recovery stage following a device implantation, and undergoing insurance issues, and patient or transplant team request for inactivation. 2
WAITLIST MANAGEMENT
Each year about 10% to 15% of the patients awaiting heart transplantation die while on the transplant list. 1 Given the scarcity of suitable organs for transplantation and the prolonged waiting time for many candidates, the CMS now requires all transplant programs to clinically reevaluate candidates on a regular basis. 17 Some patients may improve with optimal medical treatments, whereas others may deteriorate. Most ambulatory or status 2 candidates for cardiac transplant have traditionally been followed by transplant centers on the basis of the patient's condition or severity of disease. This new regulation of managing candidates awaiting transplantation, however, requires more documentation of a patient's clinical status to both ensure the patient remains a good candidate and ensure preparedness for cardiac transplantation. According to the CMS Conditions of Participation regarding waitlist management, patients who are no longer candidates must be removed from the UNOS list within 24 hours.
In 2006, the International Society for Heart and Lung Transplantation (ISHLT) published guidelines for the care of candidates for cardiac transplant. 13 Table 9 illustrates a tool for monitoring candidates for cardiac transplant on the basis of the ISHLT guidelines. For hospitalized patients, this clinical reevaluation can be easily managed and tracked. Outpatients, however, must be followed to ensure their cardiac condition has not deteriorated to a point where they develop potential contraindications to cardiac transplantation. Candidates must be evaluated for the development of malignancies or severe pulmonary hypertension during the waiting period and any end-organ damage such as renal insufficiency. Any clinical problems that would impact on the outcome of a cardiac transplantation must be followed and documented on the basis of the center's protocol. This protocol must reflect the CMS waitlist management standard. Patients who are listed as inactive, or given status 7, must also have their clinical data updated to determine whether they can be upgraded or removed from the list entirely.
ORGAN ALLOCATION
The allocation process for donor hearts was recently restructured after a year of long and heated debates. In 2005, candidates for cardiac transplant were prioritized by medical urgency within a geographic location. In this model, a donor heart from the local donor area was offered to every potential recipient on the waitlist in both statuses 1 and 2 before being offered within their zone A 500-mile radius.
On August 5, 2005 , the UNOS was charged to restructure the cardiac allocation system. The UNOS thoracic organ transplantation committee was instructed to create a system that was both fair and optimized utilization and was responsible for monitoring outcomes of patients who were either waiting or being transplanted. Many studies were conducted using the UNOS data that had been collected over the past decade. Bustami et al 18 used the Thoracic Simulated Allocation Model to look at the data collected in 2002 and concluded that prioritizing higher urgency status patients within zone A would result in a 7% mortality reduction. This would allow sicker patients to receive transplants and is believed to reduce overall deaths among waitlisted patient. 18 Lietz and Miller conducted a similar study reviewing almost 50 000 UNOS registrants between 1990 and 2005 and concluded that the status 1 patient's survival depended heavily on receiving a timely transplant. 8, [19] [20] Of interest, status 2 patients' 1-year survival while awaiting cardiac transplant was 81.4%, which is comparable with that of patients after cardiac transplantation. 8 The overall survival benefit was clearly demonstrated when organs were allocated to status 1A or 1B patients.
On November 30, 2005, the transplant news UNOS Update reported the adoption of a new cardiac allocation scheme and was predicted to result in a 7% reduction in pretransplant deaths in both adult and pediatric patients. 21 The restructured cardiac organ allocation UNOS Policy 3.7.3 went into effect in July 2006. 21 Figure 1 lists this new system allocating hearts first to status 1A and 1B patients in a regional 500-mile zone before allocating to the local status 2 patients. If the organ is not placed within this zone, it is then offered to zone B and then on to zone C per Table 9 .
MANAGING CRITICALLY ILL PATIENTS ON THE WAITLIST
Because of relatively prolonged waiting times for a suitable donor heart, the condition of candidates for cardiac transplant may deteriorate to a critical condition where pharmacologic interventions alone are no longer effective. At that time, advanced circulatory support devices can be implanted in appropriate candidates. If these machines are inserted before patients are severely compromised and recipients are bridged to transplantation, their long-term outcomes are similar to those who did not receive support. 22 Currently, there are several models and manufacturers of assist devices available to serve as a mechanical bridge to transplantation. Left ventricular assist devices (LVADs) are pumps that either replace or augment the function of a failing left ventricle. There are 2 general categories of these pumps: the world's experience is with the largest volume displacement pumps, which are by necessity produce larger pulsatile flow. This pump has numerous moving components, including motors and valves that have limited durability. generation of continuous flow rotary pumps is currently being tested in clinical trials and results are pending. These pumps appear to be more durable, less prone to infection, are clearly smaller but with proven attenuated pulsatile flow, and currently require stringent anticoagulation and anti-aggregation therapy.
LVADs AS A BRIDGE TO TRANSPLANTATION
Several models of pulsatile LVADs have been used since the late 1980s as a bridge to transplantation. Originally, these devices were air driven and required patients to remain hospitalized with large pneumatic consoles providing power to the air sack-type pump implanted in the patient's abdomen and serving as a mechanical left ventricle. Advances in technology now allow for battery-operated electromagnetic mechanical devices that permit patients to be discharged home while awaiting a suitable donor heart. Figure 2 is an example of the Thoratec Heartmate I XVE LVAD and/or RVAD with an electromechanical energy converter used in many transplant centers. In the volume displacement pumps, the Heartmate I is a pulsatile, volume displacement pump with an inflow cannula that aspirates blood from the apex of the patient's native left ventricle. The left ventricle becomes a conduit for blood pumped from the left atria to the new pneumatically powered left ventricle. An artificial inflow valve ensures blood does not flow backward into the native left ventricle. Once blood enters the mechanical ventricle, it is pumped into a cannula leading to the patient's ascending aorta. Another valve prevents blood from regurgitating back into the LVAD pumping chamber. Because the chamber collapses in a closed space during its systole, it must be vented to the atmosphere or connected to a compliance chamber to prevent vacuum formation. The Heartmate I XVE has a tube exiting through an incision in the abdomen, which serves as a vent tube and contains electrical connections to a pneumatic drive console that triggers the electrical motor, which provides the pumping action. Devices such as the LVAD have drivelines that transmit power to and get information from the pump; they are potential sources for infection. Meticulous nursing care of the driveline exit site is imperative to prevent infection.
The Heartmate II LVAD (Fig 3) is an axialflow rotary pump. It is similar to a "turbine in a tube"with 1 moving part. It does not require a compliance chamber or an air vent, and therefore has a smaller transcutaneous wire for electrical access to drive the impeller. Preliminary observational studies have shown improvements in quality of life, reduced stroke rates, reduced infection rates, and improved longevity in comparison with larger, previously tested pulsatile pumps. The randomized control trial comparing the pulsatile and nonpulsatile pumps was completed in May 2007 and full analysis of these results will not be available for 2 years. Additional flow rotary pumps include the Jarvik 2000, which is another axial-flow pump, and the Ventricor, which is a centrifugal flow pump.
In addition to the risk of infection with mechanical circulatory assist devices, patients may require intravenous inotropic therapies until hemodynamic stability is achieved. 23 Frequently, inotropic therapy and nitric oxide or other pulmonary vascular dilators are used in the short term to assist the right ventricle in recovering from the implant surgery. Complications also include hemorrhage, air embolism, and right ventricular failure in the immediate postoperative period. 24 Long-term complications include infection, thromboembolism, and device failure. 24
TOTAL ARTIFICIAL HEART AS A BRIDGE TO TRANSPLANTATION
For patients with severe biventricular heart failure, and especially in patients whom the retained heart is a liability (dysrhythmias), the total artificial heart has become an excellent bridge to cardiac transplantation. The SynCardia System's CardioWest temporary Total Artificial Heart (TAH-t) was approved by the US Food and Drug Administration for use in hospitalized patients eligible for cardiac transplantation in October 2004. The TAH-t (Fig 4) replaces both ventricles and all 4 heart valves and has been used successfully in several transplant centers across the United States. 25 The pneumatic device is implanted in the chest and is attached to the lower portion of the patient's native atria. Tubes from the mechanical ventricles extend through the patient's chest wall to a large power-generating console, often referred to as Big Blue (Fig 5) . The device can deliver up to 9.5 L/min of cardiac output. 26 This provides a more normalized hemodynamic state and increases blood flow to the kidneys and liver, thus improving the physiologic condition of a patient before cardiac transplantation.
At this time, patients on the total artificial heart must remain hospitalized; however, they are able to exercise daily with the device implanted. This device has improved the rate of survival to cardiac transplantation in critically ill patients with biventricular failure. 24 Plans for a portable total artificial heart are being reviewed by the US Food and Drug Administration. 26 
CONCLUSIONS
The roles of critical care nurses are significant in terms of identifying and managing patients who may benefit from cardiac transplantation. Understanding the patient selection criteria, the evaluation process, and the organ allocation system helps critical care nurses working with the multidisciplinary transplant team to provide education and support to patients and families about transplantation.
